AKP-11 is under clinical development by Akaal Pharma and currently in Phase II for Arthritis. According to GlobalData, Phase II drugs for Arthritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AKP-11’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AKP-11 overview

AKP-11 is under development for the treatment of pain and inflammation associated with arthritis, autoimmune diseases, pruritus, acne vulgaris, gout, alopecia areata and neuropathy pain, atopic dermatitis, mild to moderate plaque psoriasis. The drug candidate is administered both topically and orally. It is a small molecule acts by targeting sphingosine-1-phosphate (S1P) receptor 1. It is developed based on drug design and discovery technology platform. It was also under development for the treatment of multiple sclerosis and ulcerative colitis.

It was also under development for the treatment of diabetic retinopathy.

Akaal Pharma overview

Akaal Pharma is a clinical-stage drug discovery and development company that focuses on developing small-molecule drugs for the treatment of autoimmune, inflammatory and pain indications. It offers drugs candidate, which are used in the treatment of psoriasis, atopic dermatitis, multiple sclerosis, ulcerative colitis and rheumatoid arthritis. Akaal Pharma works in partnership with pharmaceutical and biotechnology companies to develop for treating various inflammatory and autoimmune diseases. The company also provides clinical studies and clinical trial services. Akaal Pharma is headquartered in Melbourne, Victoria, Australia.

For a complete picture of AKP-11’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.